Andrew M. Brunner, MD

Andrew M. Brunner, MD, discusses the most notable outcomes of the phase 2/3 IMerge trial of imetelstat in patients with low-risk myelodysplastic syndrome.

Andrew M. Brunner, MD, discusses challenges and progress in identifying treatment for patients with transfusion-dependent myelodysplastic syndromes.

Andrew M. Brunner, MD, discusses the mechanism of action of telomerase inhibitors as treatment for anemia related to myelodysplastic syndrome.

Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.